Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.
Prisons should offer abundant opportunities for HIV screening and comprehensive pre-exposure prophylaxis (PrEP) adherence programs to benefit incarcerated individuals and carceral systems as a whole.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company's work in HIV and hepatitis and how her personal background informed her team's work in developing a Covid-19 treatment.
CVS Caremark recently launched efforts to better prevent, detect and treat sickle cell disease, HIV and cardiovascular disease. CVS Caremark CMO Sree Chaguturu shared how the PBM launched this effort at the engagement track at HLTH, hosted by MedCity News
Johnson & Johnson reported results from a mid-stage study in southern Africa showing just 25% efficacy for its HIV vaccine. J&J developed the HIV vaccine with the same technology used in its successful Ebola and Covid-19 vaccines.
The therapeutic vaccine will be based on Gritstone Oncology’s technology and will use antigens from Gilead Sciences. It’s the latest in a string of partnerships Gilead has signed in its search for an HIV cure.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
UnitedHealthcare sent a notice to plan members stating that it would no longer cover Descovy to prevent HIV, while Truvada - after it goes generic next month - will be covered for free. Gilead reported that Descovy for PrEP had offset a second-quarter fall in product sales.
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead's Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
A Phase IIb/III study sponsored by NIAID is being stopped early after an interim analysis indicated that injected cabotegravir provided better protection than Gilead's Truvada.
A study, published Monday, found that when generic versions of Gilead's Truvada become available, payers should only be willing to pay a few hundred dollars more per year for Descovy, approved for PrEP in October, despite the latter's better toxicity profile.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
The social media company last month began taking down ads for lawsuits over Gilead's Truvada after complaints from LGBT and HIV organizations. However, several such ads have continued appearing on the platform, including one updated Monday that linked the drug to injuries.
News media reported that the social media company began taking down ads for lawsuits against Gilead Sciences regarding the drug Truvada following widespread outcry from LGBT and HIV groups and health experts.
In an announcement over the weekend, the British drugmaker said the FDA had cited manufacturing issues in its complete response letter for cabotegravir and rilpivirine.
The Ready, Set, PrEP program is designed to provide Gilead Sciences' Truvada and Descovy to up to 200,000 people who do not have prescription drug insurance coverage. Gilead is donating supplies of both drugs.
The agency announced it had authorized Vela Diagnostics' Sentosa SQ HIV Genotyping Assay, designed to help healthcare providers tailor antiviral therapy based on the presence of viral resistance mutations.